Leo James

Who they are

Leo James is a Cambridge-based founder — possibly co-founded TRIMTECH Therapeutics, a biotech focused on ubiquitin chains and protein degradation.

Person

Possibly — Leo James is based in Cambridge, UK, and is likely operating in the biotech or life-sciences space. Possibly — he co-founded TRIMTECH Therapeutics, a company working on ubiquitin chains and protein degradation, which places him in the targeted protein degradation field — one of the more active areas of academic-to-commercial translation in UK biotech. Cambridge as a base fits that profile closely, given the density of spinouts from the university and Wellcome Sanger ecosystem there. Beyond TRIMTECH, the available signals are thin — no prior roles, education, or career arc are on record.

How they likely show up

  • Possibly — founder role type pattern → likely used to wearing multiple hats and making decisions with incomplete information.
  • Possibly — Cambridge base in biotech → probably operates at the interface of academic research and early commercial development, where scientific credibility matters as much as business instinct.
  • Possibly — focus on ubiquitin chains and protein degradation → suggests deep technical specialisation; likely expects conversations to get into the science quickly.

Conversation tips

  • → Come prepared on the biology — ubiquitin-mediated protein degradation is a specific mechanistic area; generic biotech talk will fall flat.
  • → Ask about the Cambridge spinout context — if TRIMTECH came out of an academic lab, the founding story will matter to him.
  • → Don't assume a commercial-first orientation; at this stage he may be as focused on the science and IP as on go-to-market.

Toolbox

Openers

  • Open on TRIMTECH Therapeutics and the protein degradation angle — targeted protein degradation (TPD) is one of the most competitive areas in drug discovery right now, and asking what distinguishes TRIMTECH's approach to ubiquitin chains is a specific, credible opener.
  • Reference the Cambridge biotech ecosystem — the density of spinouts and the Wellcome/MRC funding environment is a natural shared frame if he's based there and working in this space.
  • Mention the broader TPD field momentum — companies like Arvinas and C4 Therapeutics have raised the profile of degrader-based drugs; asking where TRIMTECH sits relative to that wave is a pointed, informed question.

Discovery questions

  1. What aspect of ubiquitin chain biology is TRIMTECH's work centred on — is it E3 ligase recruitment, chain linkage selectivity, or something further upstream?
  2. How did TRIMTECH get started — did it come out of a specific lab or research programme in Cambridge?
  3. What's the biggest scientific or translational challenge you're working through right now on the protein degradation side?

Avoid

Don't treat this as a generalist biotech conversation — the ubiquitin/protein degradation focus is highly specific, and vague references to 'the exciting space of gene therapy or CRISPR' will signal you haven't done the work.

Make it yours

Tailor these openers to what you sell

These openers are generic. Sign in and tell Brief what you sell — it rewrites the hooks and questions around your pitch.

Sources

Brief on your next meeting?

Type any name. Get a structured pre-meeting brief in seconds.

Try Brief →

Generated by briefthecall.com from public web sources on November 4, 2026. Each claim is linked to its source above.

Automatically generated by AI from public sources. May be inaccurate or out of date. Remove or correct this profile →